Indivi Nets $16.8M for Alzheimer's Biomarker Discovery
November 20, 2025, 3:35 am
Indivi secured CHF 15 million. This will boost Alzheimer's drug development. The company will launch a trial in 2026. It seeks better biomarkers. This aims to improve treatment efficacy. The funds will advance precision medicine. This targets early-phase neuroscience.
Basel-based Indivi gains $16.8M. It will fuel Alzheimer's research. The funding came via a CHF 15 million round. Ava Investors led the investment.
The money will speed up Indivi's tech. It targets early-stage drug development. Focus is on Alzheimer's disease. A proof-of-concept trial launches in 2026.
Indivi seeks better biomarkers. These will show drug response. The focus is on β-amyloid therapies. Current methods lack sensitivity. New biomarkers could improve trials. They could detect treatment efficacy sooner.
Neuroscience faces tough challenges. Developing effective therapies is hard. Indivi aims to raise success rates. It integrates deep phenotyping tech. This enhances drug development.
Indivi's platform captures early benefits. It focuses on complex neurological diseases. Proprietary software drives deep phenotyping. The approach combines measurements. Electrophysiology is key. Sensor data is vital. The goal: faster, clearer proof of concept.
Indivi targets many conditions. These include multiple sclerosis. Parkinson's disease is another. Alzheimer's and related dementias are key. Muscular dystrophies are also in focus.
A partnership with Clouds of Care exists. This creates a unified R&D framework. It supports multimodal deep phenotyping. It accelerates early-stage drug development.
Indivi enhances clinical endpoints. This de-risks early development. Success rates rise. Regulatory approval becomes more likely. Risk-adjusted value increases. This benefits biopharma partners. They seek therapies for neurodegeneration.
Indivi develops digital biomarkers. Digital health technologies are vital. These tools accelerate drug development. They also personalize care. Focus is on neurodegenerative diseases. Neuroimmune diseases are also targeted.
Smartphones become measurement systems. Other devices are used too. They capture motor data. Cognitive data is collected. Vision and voice endpoints are measured. Pipelines ensure data quality. Feature extraction is validated.
These endpoints suit randomized trials. They work for regulatory science. They de-risk development. They provide precise observations. Data is continuous and rich. Traditional assessments are less effective.
This funding enables the 2026 trial. It will identify biomarkers. Electrophysiological markers are crucial. They must show superior drug response. The target: Alzheimer's modification. Beta-amyloid depletion is the method.
The trial aims to establish new biomarkers. These must be more responsive. This increases the odds of definitive signals. Early-stage Alzheimer's trials will benefit.
Indivi Nets $16.8M for Alzheimer's Biomarker Discovery
Basel-based Indivi gains $16.8M. It will fuel Alzheimer's research. The funding came via a CHF 15 million round. Ava Investors led the investment.
The money will speed up Indivi's tech. It targets early-stage drug development. Focus is on Alzheimer's disease. A proof-of-concept trial launches in 2026.
Indivi seeks better biomarkers. These will show drug response. The focus is on β-amyloid therapies. Current methods lack sensitivity. New biomarkers could improve trials. They could detect treatment efficacy sooner.
Neuroscience faces tough challenges. Developing effective therapies is hard. Indivi aims to raise success rates. It integrates deep phenotyping tech. This enhances drug development.
Indivi's platform captures early benefits. It focuses on complex neurological diseases. Proprietary software drives deep phenotyping. The approach combines measurements. Electrophysiology is key. Sensor data is vital. The goal: faster, clearer proof of concept.
Indivi targets many conditions. These include multiple sclerosis. Parkinson's disease is another. Alzheimer's and related dementias are key. Muscular dystrophies are also in focus.
A partnership with Clouds of Care exists. This creates a unified R&D framework. It supports multimodal deep phenotyping. It accelerates early-stage drug development.
Indivi enhances clinical endpoints. This de-risks early development. Success rates rise. Regulatory approval becomes more likely. Risk-adjusted value increases. This benefits biopharma partners. They seek therapies for neurodegeneration.
Indivi develops digital biomarkers. Digital health technologies are vital. These tools accelerate drug development. They also personalize care. Focus is on neurodegenerative diseases. Neuroimmune diseases are also targeted.
Smartphones become measurement systems. Other devices are used too. They capture motor data. Cognitive data is collected. Vision and voice endpoints are measured. Pipelines ensure data quality. Feature extraction is validated.
These endpoints suit randomized trials. They work for regulatory science. They de-risk development. They provide precise observations. Data is continuous and rich. Traditional assessments are less effective.
This funding enables the 2026 trial. It will identify biomarkers. Electrophysiological markers are crucial. They must show superior drug response. The target: Alzheimer's modification. Beta-amyloid depletion is the method.
The trial aims to establish new biomarkers. These must be more responsive. This increases the odds of definitive signals. Early-stage Alzheimer's trials will benefit.